FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Yuichi Kamikubo

Research Profile

Chemicals & Drugs

Phenomena

Protein Binding

Concepts & Ideas

Co-author Network

Publications

TOP 3
Yuichi Kamikubo; Jaap G Neels; Bernard Degryse
Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein.
Yuichi Kamikubo; Claudia Dellas; David J Loskutoff; James P Quigley; Zaverio M Ruggeri
Contribution of leptin receptor N-linked glycans to leptin binding.
Yuichi Kamikubo; Gerard Kroon; Scott A Curriden; H Jane Dyson; David J Loskutoff
The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Yuichi Kamikubo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2009: Yuichi Kamikubo; Jaap G Neels; Bernard Degryse
Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein.
The international journal of biochemistry & cell biology 2009;41(3):578-85.
2008: Yuichi Kamikubo; Claudia Dellas; David J Loskutoff; James P Quigley; Zaverio M Ruggeri
Contribution of leptin receptor N-linked glycans to leptin binding.
The Biochemical journal 2008;410(3):595-604.
2006: Yuichi Kamikubo; Gerard Kroon; Scott A Curriden; H Jane Dyson; David J Loskutoff
The reduced, denatured somatomedin B domain of vitronectin refolds into a stable, biologically active molecule.
Biochemistry 2006;45(10):3297-306.
2005: Kazuhiko Tomokiyo; Yuichi Kamikubo; Takako Hanada; Tatsuya Araki; Yasushi Nakatomi; Yoichi Ogata; Stephanie M Jung; Tomohiro Nakagaki; Masaaki Moroi
Von Willebrand factor accelerates platelet adhesion and thrombus formation on a collagen surface in platelet-reduced blood under flow conditions.
Blood 2005;105(3):1078-84.
2004: Naoki Ohkura; Sayuri Hiraishi; Hiroyuki Itabe; Tsutomu Hamuro; Yuichi Kamikubo; Tatsuya Takano; Juzo Matsuda; Shuichi Horie
Oxidized phospholipids in oxidized low-density lipoprotein reduce the activity of tissue factor pathway inhibitor through association with its carboxy-terminal region.
Antioxidants & redox signaling 2004;6(4):705-12.
2004: Yuichi Kamikubo; Roberto N De Guzman; Gerard Kroon; Scott A Curriden; Jaap G Neels; Michael J Churchill; Philip Dawson; Stanisław Ołdziej; Anna Jagielska; Harold A Scheraga; David J Loskutoff; H Jane Dyson
Disulfide bonding arrangements in active forms of the somatomedin B domain of human vitronectin.
Biochemistry 2004;43(21):6519-34.
2004: Bernard Degryse; Jaap G Neels; Ralf-Peter Czekay; Kathleen Aertgeerts; Yuichi Kamikubo; David J Loskutoff
The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.
The Journal of biological chemistry 2004;279(21):22595-604.
2002: Yuichi Kamikubo; Yuushi Okumura; David J Loskutoff
Identification of the disulfide bonds in the recombinant somatomedin B domain of human vitronectin.
The Journal of biological chemistry 2002;277(30):27109-19.
2002: Xinyan Xu; Ryo Takano; Yoshihisa Nagai; Tadatoshi Yanagida; Kaeko Kamei; Hisao Kato; Yuichi Kamikubo; Yo Nakahara; Kousuke Kumeda; Saburo Hara
Effect of heparin chain length on the interaction with tissue factor pathway inhibitor (TFPI).
International journal of biological macromolecules 2002;30(3-4):151-60.
2002: Yuushi Okumura; Yuichi Kamikubo; Scott A Curriden; Jieyi Wang; Tatsuto Kiwada; Shiroh Futaki; Kouki Kitagawa; David J Loskutoff
Kinetic analysis of the interaction between vitronectin and the urokinase receptor.
The Journal of biological chemistry 2002;277(11):9395-404.
2002: Shuichi Horie; Sayuri Hiraishi; Tsutomu Hamuro; Yuichi Kamikubo; Juzo Matsuda
Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
Thrombosis and haemostasis 2002;87(1):80-5.
2000: Yuichi Kamikubo; S Miyamoto; A Iwasa; M Ishii; K Okajima
Purification and characterization of factor VII inhibitor found in a patient with life threatening bleeding.
Thrombosis and haemostasis 2000;83(1):60-4.
2000: A Kawaguchi; Y Miyao; T Noguchi; H Nonogi; M Yamagishi; K Miyatake; Yuichi Kamikubo; Kousuke Kumeda; M Tsushima; A Yamamoto; Hisao Kato
Intravascular free tissue factor pathway inhibitor is inversely correlated with HDL cholesterol and postheparin lipoprotein lipase but proportional to apolipoprotein A-II.
Arteriosclerosis, thrombosis, and vascular biology 2000;20(1):251-8.
1999: Naoki Ohkura; G Soe; I Kohno; Kousuke Kumeda; H Wada; Yuichi Kamikubo; H Shiku; Hisao Kato
Monoclonal antibody specific for tissue factor pathway inhibitor-factor Xa complex: its characterization and application to plasmas from patients with disseminated intravascular coagulation and pre-disseminated intravascular coagulation.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1999;10(6):309-19.
1999: C Hine; K i Enjyoji; Koichi Kokame; S Nakamura; A Takei; Yuichi Kamikubo; K Sueishi; Hisao Kato
Monkey hepatocytes efficiently express tissue factor pathway inhibitor (TFPI), in contrast with human and rat hepatocytes.
Journal of biochemistry 1999;125(6):1039-47.
1998: Z Ye; Ryo Takano; K Hayashi; T V Ta; Hisao Kato; Yuichi Kamikubo; Y Nakahara; Kousuke Kumeda; Saburo Hara
Structural requirements of human tissue factor pathway inhibitor (TFPI) and heparin for TFPI-heparin interaction.
Thrombosis research 1998;89(6):263-70.
1998: Yuichi Kamikubo; Tsutomu Hamuro; S Takemoto; Yo Nakahara; S Kamei; Tomohiro Nakagaki; S Miyamoto; A Funatsu; H Kato
A kinetic analysis of the interaction of human recombinant tissue factor pathway inhibitor with factor Xa utilizing and immunoassay and the effect of antithrombin III/heparin on the complex formation.
Thrombosis research 1998;89(4):179-86.
1998: Tsutomu Hamuro; Yuichi Kamikubo; Yo Nakahara; S Miyamoto; A Funatsu
Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells.
FEBS letters 1998;421(3):197-202.
1997: Koichi Kaikita; Hisao Ogawa; Hirofumi Yasue; Motohiro Takeya; Kiyoshi Takahashi; T Saito; K Hayasaki; K Horiuchi; A Takizawa; Yuichi Kamikubo; Shota Nakamura
Tissue factor expression on macrophages in coronary plaques in patients with unstable angina.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(10):2232-7.
1997: Naoki Ohkura; K i Enjyoji; Yuichi Kamikubo; Hisao Kato
A novel degradation pathway of tissue factor pathway inhibitor: incorporation into fibrin clot and degradation by thrombin.
Blood 1997;90(5):1883-92.
1997: Hisakazu Suefuji; Hisao Ogawa; Hirofumi Yasue; Koichi Kaikita; Hirofumi Soejima; Takeshi Motoyama; Yuji Mizuno; Shuichi Oshima; T Saito; I Tsuji; Kousuke Kumeda; Yuichi Kamikubo; Shota Nakamura
Increased plasma tissue factor levels in acute myocardial infarction.
American heart journal 1997;134(2 Pt 1):253-9.
1997: H Nagase; K i Enjyoji; Yuichi Kamikubo; K T Kitazato; Kenji Kitazato; H Saito; Hisao Kato
Effect of depolymerized holothurian glycosaminoglycan (DHG) on tissue factor pathway inhibitor: in vitro and in vivo studies.
Thrombosis and haemostasis 1997;78(2):864-70.
1997: Yuichi Kamikubo; Yo Nakahara; S Takemoto; Tsutomu Hamuro; S Miyamoto; A Funatsu
Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells.
FEBS letters 1997;407(1):116-20.
1997: Yo Nakahara; S Takemoto; Yuichi Kamikubo; S Miyamoto
[Vascular smooth muscle cell and extrinsic coagulation pathway].
Rinsho byori. The Japanese journal of clinical pathology 1997;Suppl 104():205-15.
1996: Yuichi Kamikubo; Tsutomu Hamuro; J Matsuda; N Shinya; S Miyamoto; A Funatsu; H Kato
Antithrombotic effect of human recombinant tissue factor pathway inhibitor on endotoxin-induced intravascular coagulation in rats: concerted effect with antithrombin.
Thrombosis and haemostasis 1996;76(4):621-6.
1996: Yuichi Kamikubo; Tsutomu Hamuro; J Matsuda; S Kamei; K Jyu-ri; S Miyamoto; A Funatsu; H Kato
The clearance of proteoglycan-associated human recombinant tissue factor pathway inhibitor (h-rTFPI) in rabbits: a complex formation of h-rTFPI with factor Xa promotes a clearance rate of h-rTFPI.
Thrombosis research 1996;83(2):161-73.
1996: T Kokawa; K Enjyoji; K Kumeda; Yuichi Kamikubo; Mariko Harada-Shiba; H Koh; M Tsushima; Akira Yamamoto; H Kato
Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.
Arteriosclerosis, thrombosis, and vascular biology 1996;16(6):802-8.
1995: T Abumiya; K Enjyoji; T Kokawa; Yuichi Kamikubo; H Kato
An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.
Journal of biochemistry 1995;118(1):178-82.
1995: K Enjyoji; T Miyata; Yuichi Kamikubo; H Kato
Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Biochemistry 1995;34(17):5725-35.
1994: S Kamei; Yuichi Kamikubo; Tsutomu Hamuro; H Fujimoto; M Ishihara; H Yonemura; S Miyamoto; A Funatsu; K Enjyoji; T Abumiya
Amino acid sequence and inhibitory activity of rhesus monkey tissue factor pathway inhibitor (TFPI): comparison with human TFPI.
Journal of biochemistry 1994;115(4):708-14.